ARWR – Arrowhead Pharmaceuticals, Inc.
ARWR — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
7.27
Margin Of Safety %
Put/Call OI Ratio
0.66
EPS Next Q Diff
-0.01
EPS Last/This Y
-3.29
EPS This/Next Y
-1.38
Price
87.66
Target Price
111.2
Analyst Recom
1.14
Performance Q
12.44
Upside
-133.2%
Beta
1.29
Ticker: ARWR
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | ARWR | 74.14 | 0.37 | 1.80 | 40429 |
| 2026-07-14 | ARWR | 71.93 | 0.41 | 0.67 | 42141 |
| 2026-07-15 | ARWR | 71.83 | 0.45 | 0.23 | 43111 |
| 2026-07-16 | ARWR | 71.37 | 0.45 | 2.14 | 43297 |
| 2026-07-17 | ARWR | 74.34 | 0.46 | 1.42 | 43381 |
| 2026-07-20 | ARWR | 71.66 | 0.61 | 0.26 | 40655 |
| 2026-07-21 | ARWR | 74.52 | 0.61 | 0.12 | 41007 |
| 2026-07-22 | ARWR | 88.66 | 0.60 | 1.43 | 42184 |
| 2026-07-23 | ARWR | 86.78 | 0.66 | 0.35 | 44731 |
| 2026-07-24 | ARWR | 85.96 | 0.66 | 0.68 | 44923 |
| 2026-07-27 | ARWR | 85.53 | 0.66 | 0.60 | 44842 |
| 2026-07-28 | ARWR | 85.76 | 0.65 | 0.67 | 44979 |
| 2026-07-29 | ARWR | 86.2 | 0.67 | 0.02 | 45831 |
| 2026-07-30 | ARWR | 87.3 | 0.66 | 0.18 | 46147 |
| 2026-07-31 | ARWR | 84.7 | 0.65 | 1.20 | 46403 |
| 2026-08-03 | ARWR | 85.93 | 0.66 | 0.33 | 46732 |
| 2026-08-04 | ARWR | 93.15 | 0.65 | 0.05 | 46984 |
| 2026-08-05 | ARWR | 86.9 | 0.65 | 0.35 | 47263 |
| 2026-08-06 | ARWR | 85.87 | 0.65 | 1.82 | 47896 |
| 2026-08-07 | ARWR | 87.7 | 0.66 | 1.23 | 47910 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | ARWR | 74.14 | 3.5 | - | -3.00 |
| 2026-07-14 | ARWR | 71.87 | 3.5 | - | -3.00 |
| 2026-07-15 | ARWR | 71.82 | 3.5 | - | -3.00 |
| 2026-07-16 | ARWR | 71.37 | 3.5 | - | -3.00 |
| 2026-07-17 | ARWR | 74.33 | 2.2 | - | -3.07 |
| 2026-07-20 | ARWR | 71.66 | 2.2 | - | -3.07 |
| 2026-07-21 | ARWR | 74.48 | 2.2 | - | -3.08 |
| 2026-07-22 | ARWR | 88.65 | 2.2 | - | -3.08 |
| 2026-07-23 | ARWR | 86.77 | 2.2 | - | -3.08 |
| 2026-07-24 | ARWR | 85.64 | 2.2 | - | -3.08 |
| 2026-07-27 | ARWR | 85.54 | 2.2 | - | -3.08 |
| 2026-07-28 | ARWR | 85.76 | 2.2 | - | -3.08 |
| 2026-07-29 | ARWR | 86.23 | 2.2 | - | -3.08 |
| 2026-07-30 | ARWR | 87.39 | 2.2 | - | -3.08 |
| 2026-07-31 | ARWR | 84.69 | 2.2 | - | -3.08 |
| 2026-08-03 | ARWR | 85.99 | 2.2 | - | -3.08 |
| 2026-08-04 | ARWR | 85.99 | 2.2 | - | -3.08 |
| 2026-08-05 | ARWR | 86.86 | 2.2 | - | -3.11 |
| 2026-08-06 | ARWR | 85.80 | 2.2 | - | -3.11 |
| 2026-08-07 | ARWR | 87.66 | -100.0 | - | -3.30 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | ARWR | -0.42 | 4.93 | 6.37 |
| 2026-07-14 | ARWR | -0.42 | 4.93 | 6.37 |
| 2026-07-15 | ARWR | -0.42 | 4.93 | 6.37 |
| 2026-07-16 | ARWR | -0.42 | 4.93 | 6.37 |
| 2026-07-17 | ARWR | -0.42 | 4.93 | 6.37 |
| 2026-07-20 | ARWR | -0.42 | 5.04 | 6.37 |
| 2026-07-21 | ARWR | -0.42 | 5.04 | 6.36 |
| 2026-07-22 | ARWR | -0.43 | 5.04 | 6.36 |
| 2026-07-23 | ARWR | -0.43 | 5.04 | 6.36 |
| 2026-07-24 | ARWR | -0.43 | 5.04 | 6.36 |
| 2026-07-27 | ARWR | -0.43 | 5.14 | 7.27 |
| 2026-07-28 | ARWR | -0.43 | 5.14 | 7.27 |
| 2026-07-29 | ARWR | -0.43 | 5.14 | 7.27 |
| 2026-07-30 | ARWR | -0.43 | 5.14 | 7.27 |
| 2026-07-31 | ARWR | -0.43 | 5.14 | 7.27 |
| 2026-08-03 | ARWR | -0.43 | 3.76 | 7.27 |
| 2026-08-04 | ARWR | -0.43 | 3.76 | 7.27 |
| 2026-08-05 | ARWR | -0.43 | 3.76 | 7.27 |
| 2026-08-06 | ARWR | -0.43 | 3.76 | 7.27 |
| 2026-08-07 | ARWR | -0.43 | 3.76 | 7.27 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.36
Avg. EPS Est. Current Quarter
-1.28
Avg. EPS Est. Next Quarter
-1.37
Insider Transactions
-0.43
Institutional Transactions
3.76
Beta
1.29
Average Sales Estimate Current Quarter
70
Average Sales Estimate Next Quarter
40
Fair Value
Quality Score
27
Growth Score
35
Sentiment Score
65
Actual DrawDown %
8.2
Max Drawdown 5-Year %
-87.9
Target Price
111.2
P/E
Forward P/E
PEG
P/S
18.49
P/B
26.57
P/Free Cash Flow
EPS
-2.24
Average EPS Est. Cur. Y
-3.3
EPS Next Y. (Est.)
-4.68
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
-47.79
Relative Volume
0.43
Return on Equity vs Sector %
-96.1
Return on Equity vs Industry %
-80
EPS 1 7Days Diff
-0.2
EPS 1 30Days Diff
-0.3
EBIT Estimation
◆
ARWR
Healthcare
$87.65
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
58.4
Range 1M
67.4%
Sup Dist
3.3%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-35033.3%
EPS NY
-34.2%
52W%
89.6%
Long-Term Value
Quality companies, undervalued
WEAK
🟡 HOLD
+26.9% upside
Upside
+26.9%
Quality
27
ARWR — P/E HistoricalBiotechnology
Arrowhead Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 711
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
ARWR
Latest News
—
Caricamento notizie per ARWR…
stock quote shares ARWR – Arrowhead Pharmaceuticals, Inc. Stock Price stock today
news today ARWR – Arrowhead Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ARWR – Arrowhead Pharmaceuticals, Inc. yahoo finance google finance
stock history ARWR – Arrowhead Pharmaceuticals, Inc. invest stock market
stock prices ARWR premarket after hours
ticker ARWR fair value insiders trading